QIAGEN And INOVIO Expand Collaboration To Develop NGS Companion Diagnostics For INOVIOs VGX-3100 For Advanced Cervical Dysplasia

QIAGEN and INOVIO Pharmaceuticals gave announced the expansion of their partnership through a new framework agreement for the development of liquid biopsy companion diagnostic products based on NGS technology (Next Generation Sequencing) to complement INOVIO's therapies. The initial project of this expanded collaboration is the joint development of a diagnostic test to identify women most likely to benefit from the clinical application of VGX-3100, INOVIO's immunotherapy for the treatment of advanced cervical dysplasia associated with the human papillomavirus (HPV) in Be connected, be able to benefit. QIAGEN's bioinformatics expertise will further increase the predictive accuracy of INOVIO's tentative biomarker signature. The test is now being developed for use on the Illumina NextSeq ™ 550Dx platform. It is the first development based on a partnership signed between QIAGEN and Illumina in October 2019. VGX-3100 is INOVIO's active ingredient for late-stage DNA immunotherapy. It is currently in two Phase 3 studies (REVEAL 1 and REVEAL 2) and could become the first non-surgical treatment for advanced, precancerous lesions of the cervix associated with the virus (HPV-16 and HPV-18) . “As we continue to develop our DNA drug platform, we are always looking for ways to drive innovation with our own technology or that of a creative and competent partner. QIAGEN has an extensive track record in developing and commercializing novel diagnostic tests, ”said Dr. J. Joseph Kim, President and CEO of INOVIO. “INOVIO is developing VGX-3100 as a non-surgical treatment approach for precancerous diseases of the cervix. The biomarker-based pretreatment that we have discovered could provide a targeted way of pinpointing the patients who are most likely to respond to treatment. Our goal is to increase the absolute effectiveness of immunotherapy. "

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!